Tumor Microenvironment Laboratory, UMR3347 CNRS/U1021 INSERM, Institut Curie, Orsay, France.
Human Neurosciences Department, Neurosurgery Division, Sapienza University, Rome, Italy.
Front Immunol. 2024 Feb 29;15:1347877. doi: 10.3389/fimmu.2024.1347877. eCollection 2024.
Glioblastoma is a highly aggressive and invasive tumor that affects the central nervous system (CNS). With a five-year survival rate of only 6.9% and a median survival time of eight months, it has the lowest survival rate among CNS tumors. Its treatment consists of surgical resection, subsequent fractionated radiotherapy and concomitant and adjuvant chemotherapy with temozolomide. Despite the implementation of clinical interventions, recurrence is a common occurrence, with over 80% of cases arising at the edge of the resection cavity a few months after treatment. The high recurrence rate and location of glioblastoma indicate the need for a better understanding of the peritumor brain zone (PBZ). In this review, we first describe the main radiological, cellular, molecular and biomechanical tissue features of PBZ; and subsequently, we discuss its current clinical management, potential local therapeutic approaches and future prospects.
胶质母细胞瘤是一种高度侵袭性和浸润性的肿瘤，影响中枢神经系统（CNS）。其五年生存率仅为 6.9%，中位生存时间为 8 个月，是 CNS 肿瘤中生存率最低的。其治疗包括手术切除，随后进行分割放疗以及替莫唑胺联合和辅助化疗。尽管实施了临床干预，但复发是常见的，超过 80%的病例在治疗后几个月出现在切除腔边缘。胶质母细胞瘤的高复发率和位置表明需要更好地了解肿瘤周围脑区（PBZ）。在这篇综述中，我们首先描述了 PBZ 的主要放射学、细胞、分子和生物力学组织特征；随后，我们讨论了其目前的临床管理、潜在的局部治疗方法和未来的前景。
